Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (HKG:9989)

Hong Kong · Delayed Price · Currency is HKD

4.210

-0.010 (-0.24%)

Jul 10, 2026, 4:08 PM HKT

-22.61% (1Y)

Market Cap	14.68B -20.1%
Revenue (ttm)	6.16B +2.1%
Net Income	432.46M -41.3%
EPS	0.29 -41.3%
Shares Out	n/a
PE Ratio	33.95
Forward PE	n/a
Dividend	0.17 (3.94%)
Ex-Dividend Date	May 27, 2026

Volume	624,000
Open	4.140
Previous Close	4.220
Day's Range	4.120 - 4.330
52-Week Range	3.740 - 7.260
Beta	0.31
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 29, 2026

About HKG:9989

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Pharmaceutical preparations, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers pharmaceutical preparations products, such as enoxaparin sodium injection; API products, including heparin and enoxaparin sodium APIs. It also provides molecule biologics CDMO services, which include... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1998

Employees 2,150

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 9989

Financial Performance

In 2025, HKG:9989's revenue was 5.48 billion, an increase of 3.75% compared to the previous year's 5.28 billion. Earnings were 349.49 million, a decrease of -45.96%.

Financial numbers in CNY Financial Statements